Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9359667 | The Spine Journal | 2005 | 6 Pages |
Abstract
Though one must be careful in extrapolating animal data to humans, this study suggests that calcitonin is not detrimental to spine fusion. Pamidronate, however, does lead to a mechanically less robust fusion. Based on this study, there is no evidence to support a recommendation to stop antiresorptive therapy for osteoporosis in the spine fusion patient.
Related Topics
Health Sciences
Medicine and Dentistry
Orthopedics, Sports Medicine and Rehabilitation
Authors
L. Brett MD, Robert MD, Ryan BSBME, Lisa MS, Moon-Jun MD,